Jiangsu Qianren Biotechnology

Jiangsu Qianren Biotechnology Co., Ltd. is a holding company established in 2016 and based in Jiangsu, China. The company focuses on the research and development of biological products and Class I medical devices.

The firm is actively engaged in the pharmaceutical sector, conducting numerous clinical trials to establish the bioequivalence of its drug products against existing market leaders. Notable trials include studies on Teneligliptin Hydrobromide tablets for diabetes, Riociguat tablets for pulmonary hypertension in comparison to Bayer AG's product, and Sitagliptin with Metformin extended-release tablets. These trials are a core part of its business model, which centers on developing and bringing generic or improved versions of established drugs to the market. The company's operations involve randomized, open-label, single-dose, and crossover studies under both fasting and fed conditions to meet regulatory standards for bioequivalence.

As of early 2016, the company's business scope was defined to include biological products and R&D, and it holds a number of patents in its field.

Keywords: bioequivalence studies, clinical trials, pharmaceutical development, generic drugs, drug pipeline, Teneligliptin, Riociguat, Sitagliptin, biological products, Chinese biotechnology, pharmaceutical R&D, medical devices, holding company, diabetes treatment, pulmonary hypertension treatment